BYCHOWSKI, Mateusz, KWAŚNA, Julia, GÓRSKI, Mateusz, ZAŁĘSKA, Adrianna, KAŹMIERCZYK, Izabela, LENART, Kacper, HOMZA, Michał, ZAKRZEWSKA, Natalia, BEDNAREK, Szymon and KULICKA, Joanna. Recent Advances in Bacopa Monnieri Research: Neuroprotective Effects and Cognitive Decline Mitigation in Neurodegenerative Diseases with a Focus on Alzheimer's and Parkinson's Diseases. Quality in Sport. 2024;35:56377 eISSN 2450-3118.
https://dx.doi.org/10.12775/QS.2024.35.56377
https://apcz.umk.pl/QS/article/view/56377

The journal has been 20 points in the Ministry of Higher Education and Science of Poland parametric evaluation. Annex to the announcement of the Minister of Higher Education and Science of 05.01.2024. No. 32553.
Has a Journal's Unique Identifier: 201398. Scientific disciplines assigned: Economics and finance (Field of social sciences); Management and Quality Sciences (Field of social sciences).
Punkty Ministerialne z 2019 - aktualny rok 20 punktów. Załącznik do komunikatu Ministra Szkolnictwa Wyższego i Nauki z dnia 05.01.2024 r. Lp. 32553. Posiada Unikatowy Identyfikator Czasopisma: 201398.
Przypisane dyscypliny naukowe: Ekonomia i finanse (Dziedzina nauk społecznych); Nauki o zarządzaniu i jakości (Dziedzina nauk społecznych).

The authors declare that there is no conflict of interests regarding the publication of this paper.
Received: 23.11.2024. Revised: 05.12.2024. Accepted: 08.12.2024. Published: 08.12.2024.

Recent Advances in Bacopa Monnieri Research: Neuroprotective Effects and Cognitive Decline Mitigation in Neurodegenerative Diseases with a Focus on Alzheimer's and Parkinson's Diseases

Mateusz Bychowski, Julia Kwaśna, Mateusz Górski, Adrianna Załęska, Izabela Kaźmierczyk, Kacper Lenart, Michał Homza, Natalia Zakrzewska, Szymon Bednarek, Joanna Kulicka

Mateusz Bychowski
Medical University of Lodz, Poland
https://orcid.org/0009-0004-9034-2756
mateusz.bychowski@stud.umed.lodz.pl

Julia Kwaśna
Medical University of Gdansk, Poland
https://orcid.org/0009-0006-2314-2329
juliakwasna@gumed.edu.pl

Mateusz Górski
Medical University of Lodz, Poland
https://orcid.org/0009-0003-3473-132X
mateusz.gorski1@stud.umed.lodz.pl

Adrianna Załęska
Medical University of Lodz, Poland
https://orcid.org/0009-0004-6772-3956
adrianna.zaleska@stud.umed.lodz.pl

Izabela Kaźmierczyk
Medical University of Lodz, Poland
https://orcid.org/0009-0006-7798-7765
izabela.kazmierczyk@stud.umed.lodz.pl

Kacper Lenart
Medical University of Lodz, Poland
https://orcid.org/0009-0003-5092-8835
Kacper.lenart@stud.umed.lodz.pl

Michał Homza
Medical University of Lodz, Poland
https://orcid.org/0009-0002-4651-5520
michal.homza@stud.umed.lodz.pl

Natalia Zakrzewska
Medical University of Lodz, Poland
https://orcid.org/0009-0003-0405-2764
natalia.zakrzewska@stud.umed.lodz.pl

Szymon Bednarek
Medical University of Lodz, Poland
https://orcid.org/0009-0001-3189-8322
szymon.bednarek@stud.umed.lodz.pl

Joanna Kulicka
Medical University of Lodz, Poland
https://orcid.org/0009-0009-1614-482X
jkulicka@gmail.com

Abstract

Background: The global rise in neurodegenerative diseases, including Alzheimer's and Parkinson's, has increased interest in natural nootropics such as Bacopa Monnieri. Known for its neuroprotective properties, Bacopa Monnieri has a long history in traditional medicine. This review examines its role in cognitive enhancement, focusing on its effects in neurodegenerative diseases.

Methods: Relevant studies published after 2020 were analyzed to assess Bacopa Monnieri's impact on memory, concentration, and neuroprotection, particularly in Alzheimer's and Parkinson's. The review explores mechanisms such as neurotransmitter modulation, reduced neuroinflammation, and enhanced synaptic plasticity.

Results: Bacopa Monnieri exhibits neuroprotective effects beneficial for cognitive health and neurodegenerative diseases. It has antioxidant and anti-inflammatory properties, promotes neurogenesis, and increases Brain-Derived Neurotrophic Factor (BDNF). In Alzheimer's models, it improved cognitive function, reduced amyloid plaques, and prevented Tau aggregation. In Parkinson's, it enhanced dopaminergic function and reduced neuroinflammation. Despite promising findings, more robust clinical trials are required to confirm its efficacy.

Conclusion: Bacopa Monnieri demonstrates potential in neuroprotection and cognitive enhancement, particularly in Alzheimer's and Parkinson's. It improves synaptic health and reduces oxidative stress and neuroinflammation. However, larger, high-quality trials are needed to fully establish its therapeutic role in neurodegenerative diseases.

Keywords:

Bacopa Monnieri, Alzheimer's Disease, Parkinson's Disease, Cognitive Decline, Neurodegenerative Diseases, Cognitive Enhancement, Neuroprotection

Introduction

The aging global population has led to a marked increase in the prevalence of neurodegenerative diseases, such as Alzheimer's and Parkinson's, creating substantial challenges for healthcare systems and society at large (Can & Sanlier, 2024). Cognitive decline, characterized by memory loss, diminished executive function, and impaired learning, is a defining feature of these conditions, profoundly impacting the quality of life in older adults (Marcos-Rabal et al., 2021). Addressing these challenges has prompted significant efforts to identify effective prevention and treatment strategies. Among the various approaches, natural nootropics and herbal supplements have gained considerable attention as promising alternatives, fueled by rising demand from both younger and older populations seeking cognitive enhancement and healthy aging (Jerom et al., 2023).

Medicinal plants, such as Bacopa Monnieri, are increasingly acknowledged for their potential as complementary interventions and as sources of novel therapies for neurodegenerative diseases (Gregory et al., 2021). A key herb in traditional Ayurvedic medicine, Bacopa Monnieri has attracted significant scientific interest for its neuroprotective and cognitive-enhancing properties (Shoukat et al., 2023). Traditionally known for its benefits in supporting memory, learning, and mental clarity, Bacopa Monnieri is now the subject of extensive research aimed at uncovering its mechanisms of action and evaluating its therapeutic potential.

Emerging evidence indicates that Bacopa Monnieri exerts its beneficial effects through multiple biological pathways, including the modulation of neurotransmitter systems, attenuation of neuroinflammation, and reduction of oxidative stress. Additionally, Bacopa Monnieri has been shown to enhance synaptic plasticity, primarily through the upregulation of AMPA receptors—essential for synaptic transmission and cognitive function (Gupta & Prasad, 2024). These properties make Bacopa Monnieri a compelling candidate for addressing cognitive decline and potentially slowing the progression of neurodegenerative diseases, such as Alzheimer's (Palollathil et al., 2024).

This review aims to synthesize recent findings, including systematic reviews and meta-analyses, to provide a comprehensive understanding of Bacopa Monnieri's effects on neurological health. By evaluating the breadth of current research, this review seeks to clarify its therapeutic potential and outline directions for future studies. Specifically, it will focus on summarizing the current knowledge regarding the influence of Bacopa Monnieri on the progression of Alzheimer's and Parkinson's diseases. In doing so, it contributes to the growing body of evidence supporting the use of Bacopa Monnieri in promoting cognitive health and combating the challenges posed by neurodegenerative diseases.

Mechanism of action

Bacopa Monnieri (BM) contains bioactive compounds, predominantly bacosides, which play a central role in its neuroprotective and cognitive-enhancing effects. The main bacosides, bacoside A and bacoside B, exert a variety of biological activities, including potent anti-inflammatory and antioxidant actions. These compounds modulate several key signaling pathways, contributing to the reduction of pro-inflammatory markers such as TNF-α, IL-6, IL-17a, and CCL5 (Valotto Neto et al., 2024). Specifically, BM has been shown to influence interleukins IL-4 and IL-13, leading to a reduction in neuroinflammatory responses in Alzheimer's disease models (Palollathil et al., 2024).

In addition to its anti-inflammatory effects, bacosides promote neurogenesis by upregulating Brain-Derived Neurotrophic Factor (BDNF) and TrkB receptor expression, both of which are crucial for cognitive function and neuronal regeneration (Banerjee et al., 2014). Mallick et al. (2024) demonstrated that the CDRI-08 extract of Bacopa Monnieri significantly enhances neurogenesis in the hippocampus of rats with hepatic encephalopathy, improving cognitive function. Furthermore, Bacopa Monnieri's antioxidant properties enable it to reduce reactive oxygen species (ROS), offering protection to neurons against oxidative stress and damage (Nopparat et al., 2024). This neuroprotective effect was further corroborated by Ghosh et al. (2024), who showed that BM extracts mitigate oxidative damage, thereby preserving neuronal integrity.

Bacosides also interact with AMPA receptors, which are essential for synaptic plasticity and memory consolidation. Research by Gupta and Prasad (2024) revealed that Bacopa Monnieri upregulates AMPA receptor expression and trafficking proteins in the hippocampus, enhancing synaptic transmission and supporting learning

and memory processes. Additionally, Bacopa Monnieri may influence Tau protein aggregation, a hallmark of Alzheimer's disease pathology. Dubey et al. (2023) provided evidence that BM reduces Tau-mediated cytotoxicity, potentially offering neuroprotective benefits and decelerating the progression of neurodegenerative diseases.

Through its diverse bioactive constituents, Bacopa Monnieri modulates various receptors and signaling pathways, influencing neuroinflammation, promoting neurogenesis, and mitigating oxidative stress. These mechanisms collectively underlie its therapeutic potential in the treatment of neurodegenerative diseases and cognitive enhancement.

Methods

This comprehensive review analyzed the neuroprotective effects of Bacopa Monnieri in the context of neurodegenerative diseases, with a particular focus on research published since 2020. To ensure a thorough understanding of the current literature, a broad search was conducted in the PubMed database using keywords: „Bacopa Monnieri", „Alzheimer's Disease", „Parkinson's Disease", „Cognitive Decline", „Neurodegenerative Diseases", „Cognitive Enhancement", „Neuroprotection". The inclusion criteria encompassed a wide range of studies, including clinical trials, experimental research, observational studies, and, notably, systematic reviews and other review articles, to provide a more complete synthesis of the existing evidence on Bacopa Monnieri.

Given the limited body of research on this herb, this approach allowed for the incorporation of both primary studies and secondary reviews to create a more robust and accurate summary of recent findings. A total of 13 recent papers were selected based on their methodological rigor and their focus on Bacopa Monnieri's pharmacological mechanisms, efficacy, and safety. These studies were critically evaluated for their contribution to understanding neuroprotection, cognitive enhancement, and the markers of neurodegeneration.

The review aimed to identify and highlight the most significant studies that could facilitate a comparative analysis of Bacopa Monnieri's effects in neurodegenerative diseases. By synthesizing results from diverse sources, we sought to provide a comprehensive summary of the current state of knowledge regarding the therapeutic potential of Bacopa Monnieri. This rigorous methodology ensured that the review captured a wide array of perspectives and findings, helping to create a more detailed and reliable understanding of the herb's role in promoting neurological health and mitigating cognitive decline.

To assess the quality and reliability of the studies included, standardized evaluation tools were used, ensuring that the findings presented in this review are grounded in sound scientific methodology.

Results

The results of this review are organized into four sections to better examine the potential mechanisms and therapeutic benefits of Bacopa Monnieri (BM). Each section delves into different aspects of its neuroprotective effects and cognitive enhancement, offering a comprehensive overview of its potential in neurodegenerative diseases and cognitive health.

1. Neuroprotective Effects of Bacopa Monnieri

Bacopa Monnieri has been increasingly recognized for its neuroprotective properties, demonstrating significant effects on neurological health across various models of neurodegeneration. Several studies have highlighted its role in protecting neurons from oxidative stress, inflammation, and neurodegeneration, marking it as a promising therapeutic agent for neurodegenerative diseases.

1.1 Neurogenesis and Brain-Derived Neurotrophic Factor (BDNF)

Mallick et al. (2024) examined the neuroprotective effects of the CDRI-08 extract of Bacopa Monnieri in male rats with moderate hepatic encephalopathy. Their study demonstrated that Bacopa Monnieri significantly restored hippocampal neurogenesis, leading to improvements in cognitive function. This neurogenic recovery

was closely associated with elevated levels of Brain-Derived Neurotrophic Factor (BDNF) and TrkB receptor expression, both of which are essential for neurogenesis and neuronal survival (Mallick et al., 2024).

1.2 Antioxidant Effects

Bacopa Monnieri's antioxidant properties are another key mechanism in its neuroprotective action. Ghosh et al. (2024) found that Bacopa Monnieri extract effectively reduced oxidative damage in neuronal cells, thus preserving cellular integrity and protecting against oxidative stress-induced neuronal injury. These findings suggest that Bacopa Monnieri may help mitigate oxidative damage, a major contributor to the progression of neurodegenerative diseases (Ghosh et al., 2024).

1.3 Anti-inflammatory Properties

In addition to its antioxidant effects, Bacopa Monnieri has been shown to possess potent anti-inflammatory properties. Palollathil et al. (2024) provided strong evidence that Bacopa Monnieri modulates key signaling pathways related to interleukins IL-4 and IL-13, resulting in a significant reduction in pro-inflammatory cytokines in Alzheimer's disease models. This suggests that Bacopa Monnieri may help attenuate neuroinflammation, a critical factor in the pathogenesis of neurodegenerative diseases. By reducing neuroinflammatory responses, Bacopa Monnieri may slow the progression of diseases like Alzheimer's, potentially enhancing cognitive health (Palollathil et al., 2024).

2. Alzheimer's Disease Research

Bacopa Monnieri has shown potential in modulating Tau protein aggregation, a hallmark of Alzheimer's disease. Dubey et al. (2023) demonstrated that Bacopa Monnieri reduced Tau-mediated cytotoxicity in cultured cells. Tau aggregation plays a pivotal role in neurodegeneration, and these findings suggest that Bacopa Monnieri may offer neuroprotective benefits by targeting Tau aggregation, thus contributing to therapies aimed at preserving cognitive function (Dubey et al., 2023).

Sushma et al. (2024) explored the effects of Bacopa Monnieri in an Alzheimer's disease-like model in rats. After four weeks of supplementation, Bacopa Monnieri improved cognitive and exploratory behaviors, reduced oxidative stress and inflammation, and restored neurotrophic factors. Furthermore, it prevented hippocampal neurodegeneration, decreased amyloid plaque accumulation, and normalized Tau pathology. Mechanistic insights revealed that Bacopa Monnieri interacts with glycogen synthase kinase-3β (GSK-3β), restoring Wnt/β-catenin signaling, thus underscoring its anti-Alzheimer potential (Sushma et a., 2024).

Agarwal et al. (2023) evaluated Bacopa Monnieri's effects on cognitive decline associated with Alzheimer's disease (AD) and its prodromal stages. While their study showed promising results, the authors acknowledged several limitations, including small sample sizes and insufficient effect size. They emphasized the need for more comprehensive diagnostic scales and adherence to rigorous standards, such as CONSORT and STROBE, to improve the quality of evidence on BM's efficacy in treating Alzheimer's and related dementias (Agarwal et al., 2023).

3. Parkinson's Disease Research

Research into Bacopa Monnieri's effects in Parkinson's disease (PD) has similarly yielded promising results. Goyal et al. (2022) demonstrated that Bacopa Monnieri plays a significant neuroprotective role in PD by reducing oxidative stress and neuroinflammation. Their study found that Bacopa Monnieri treatment increased levels of glutathione and other antioxidants in the brains of rats exposed to cigarette smoke, suggesting its potential to enhance dopaminergic neuronal function and protect against neurodegeneration (Goyal et al., 2022).

Singh et al. (2020) further explored Bacopa Monnieri's effects in regulating neuroinflammation in PD models. Their findings revealed that Bacopa Monnieri administration suppressed pro-inflammatory cytokine levels, reduced α-synuclein accumulation, and decreased the generation of reactive oxygen species (ROS). Notably, pre-treatment with Bacopa Monnieri produced more significant results than co- or post-treatment, highlighting its potential as a preventive therapeutic for Parkinson's disease.

A double-blind, controlled clinical trial by Santos et al. (2023) evaluated the effects of Bacopa Monnieri extract on Parkinson's disease symptoms in 20 patients over 90 days. While no significant changes were observed in parkinsonian symptoms or systemic functions, the higher dose of Bacopa Monnieri (450 mg/day) demonstrated

time-dependent improvements in emotional function. These findings suggest that Bacopa Monnieri may benefit emotional function in PD patients, warranting further investigation to substantiate these results and explore broader therapeutic applications.

4. Cognitive Function Enhancement

Bacopa Monnieri has been extensively studied for its cognitive-enhancing properties, particularly in neurodegenerative diseases.

A systematic review by Valotto Neto et al. (2024) underscored Bacopa Monnieri's promising effects on cognitive function. While several clinical trials suggest that Bacopa Monnieri may improve cognitive performance and mitigate neurodegeneration, the review noted significant limitations in the studies, such as small sample sizes, lack of blinding, and absence of placebo controls. These shortcomings highlight the need for well-designed randomized controlled trials (RCTs) to confirm Bacopa Monnieri's efficacy and safety across diverse neurodegenerative populations.

Gupta and Prasad (2024) investigated the effects of Bacopa Monnieri on AMPA receptor expression and trafficking proteins in the hippocampus. Their study found that Bacopa Monnieri enhanced AMPA receptor dynamics, which are crucial for synaptic plasticity and cognitive function. By improving synaptic transmission, Bacopa Monnieri may not only support cognitive enhancement but also provide neuroprotection against synaptic dysfunction, a common feature in neurodegenerative diseases.

However, some studies have not robustly supported Bacopa Monnieri's cognitive-enhancing claims. A systematic review by Basheer et al. (2022) evaluated studies comparing Bacopa Monnieri with placebo and donepezil. While some studies indicated significant cognitive improvements, the overall quality of evidence was rated as low due to small sample sizes and insufficient long-term follow-up. Nevertheless, the review concluded that Bacopa Monnieri shows potential as a complementary therapy for existing Alzheimer's disease treatments.

Discussion

The neuroprotective effects of Bacopa Monnieri (BM) have garnered increasing attention in recent years, supported by a growing body of evidence that highlights its potential to enhance cognitive function and promote brain health, particularly in the context of neurodegenerative diseases. BM has been shown to positively impact several critical processes associated with brain health, including neurogenesis, oxidative stress reduction, and the attenuation of neuroinflammation. These factors are essential for preserving cognitive function and combating neurodegenerative conditions such as Alzheimer's disease and Parkinson's disease. For example, Mallick et al. (2024) demonstrated that BM can restore hippocampal neurogenesis, a crucial process for memory and learning, while Ghosh et al. (2024) provided compelling evidence that BM effectively protects neuronal cells from oxidative damage, a key factor in neurodegeneration. Furthermore, studies by Palollathil et al. (2024) and Dubey et al. (2023) emphasize BM's role in reducing inflammation and Tau protein aggregation, both of which are implicated in the progression of neurodegenerative diseases. Understanding these molecular mechanisms is vital for leveraging BM in therapeutic interventions aimed at combating cognitive decline and neurodegeneration.

Despite the promising preclinical and clinical findings, it is important to acknowledge the limitations of the current body of literature surrounding Bacopa Monnieri. Many studies assessing its neuroprotective effects are marred by methodological weaknesses, such as small sample sizes, a lack of control groups, and inconsistencies in dosing regimens. The systematic review by Valotto Neto et al. (2024) underscores these challenges, highlighting significant variability in BM dosages and treatment durations across different trials. This inconsistency calls into question the robustness of the evidence supporting BM's efficacy, as some studies report statistically significant improvements in cognitive performance, while others show no significant difference compared to placebo or other cognitive enhancers, such as donepezil. Moreover, the high risk of bias across various studies complicates the interpretation of results, underscoring the need for caution in drawing definitive conclusions about BM's effectiveness.

Additionally, the quality and composition of commercial BM supplements remain a significant concern. As a dietary supplement, BM's availability and formulation can vary widely, which may influence the consistency and efficacy of its effects. This variability in product quality further complicates the interpretation of research findings and emphasizes the need for standardization and quality control in the production of BM supplements.

Such variability also makes it difficult to establish clear and reliable dosage guidelines, which are crucial for determining the optimal therapeutic dose for human use, especially in the context of neurodegenerative diseases.

In light of these challenges, future research must address the existing limitations by adopting more rigorous study designs. Larger participant cohorts, standardized treatment protocols, and the use of modern diagnostic scales for assessing cognitive decline—particularly in Alzheimer's disease and its prodromal stages—are necessary to enhance the validity and applicability of the findings. Moreover, adherence to established reporting guidelines, such as CONSORT and STROBE, is essential to ensure high-quality evidence that can inform clinical practice effectively.

Conclusion

This comprehensive review synthesized findings from recent research on Bacopa Monnieri (BM), highlighting its potential contributions to neurological health. The evidence supports its neuroprotective properties, particularly in enhancing cognitive function, promoting synaptic health, and mitigating neuroinflammatory responses. Studies demonstrate that BM exerts significant effects on synaptic plasticity via modulation of AMPA receptors, reduces oxidative stress, and influences pro-inflammatory cytokine pathways. Additionally, BM shows promise in conditions like Alzheimer's disease and Parkinson's disease, with reported benefits such as mitigating Tau aggregation, reducing α-synuclein accumulation, and supporting dopaminergic neurons. These findings affirm BM's multifaceted potential in addressing cognitive decline and neurodegenerative disease mechanisms.

However, while BM's cognitive-enhancing effects are relatively better substantiated than its neuroprotective and strictly therapeutic roles, several challenges remain. Despite promising data, most studies rely on preclinical models, and there is still no standardized dosage for BM in the context of neurodegenerative diseases. The variability in dosing regimens, treatment durations, and study designs limits the ability to generalize findings to human populations. Moreover, the overall quality of evidence is impacted by methodological limitations, including small sample sizes, inconsistent assessment tools, and lack of long-term follow-up.

To fully harness the therapeutic potential of BM, rigorous randomized controlled trials with larger sample sizes and standardized protocols are essential. These efforts should focus on optimizing dosage, evaluating long-term safety, and exploring BM's efficacy across diverse populations. With further advancements, BM could emerge as a viable adjunctive or preventive therapeutic agent, contributing to innovative strategies for combating neurodegenerative diseases and enhancing cognitive resilience in aging populations.

Disclosure

Author's Contribution

Conceptualization: Mateusz Bychowski, Julia Kwaśna, Szymon Bednarek, Natalia Zakrzewska

Methodology: Mateusz Bychowski, Julia Kwaśna, Szymon Bednarek, Natalia Zakrzewska

Software: Mateusz Bychowski, Julia Kwaśna, Szymon Bednarek, Natalia Zakrzewska

Check: Mateusz Bychowski, Julia Kwaśna, Szymon Bednarek, Natalia Zakrzewska

Formal analysis: Mateusz Bychowski Adrianna Załęska, Kacper Lenart, Michał Homza

Investigation: Michał Homza, Mateusz Bychowski, Iza Kaźmierczyk, Joanna Kulicka

Resources: Formal analysis: Mateusz Bychowski, Adrianna Załęska, Kacper Lenart, Michał Homza

Data curation: Formal analysis: Mateusz Bychowski, Adrianna Załęska, Kacper Lenart, Michał Homza

Writing -rough preparation: Mateusz Bychowski, Adrianna Załęska, Kacper Lenart, Mateusz Górski, Iza Kaźmierczyk, Joanna Kulicka, Natalia Zakrzewska

Writing -review and editing: Mateusz Bychowski, Adrianna Załęska, Mateusz Górski

Visualization: Formal analysis: Mateusz Bychowskii, Adrianna Załęska, Kacper Lenart, Michał Homza

Project Administration: Formal analysis: Mateusz Bychowski, Adrianna Załęska, Kacper Lenart, Michał Homza

Supervision: Mateusz Bychowski, Julia Kwaśna

All authors have read and agreed with the published version of the manuscript.

Funding Statement
This research received no external funding.

Institutional Review Board Statement
Not applicable

Informed Consent Statement
Not applicable

Data Availability Statement
The authors confirm that the data supporting the findings of this study are available within the article's bibliography

Conflict of Interest Statement
The authors declare no conflict of interest.

References

1. Agarwal, A., Mishra, B., Gupta, A., Srivastava, M. V. P., Basheer, A., Sharma, J., & Vishnu, V. Y. (2023). Importance of high-quality evidence regarding the use of Bacopa monnieri in dementia. *Frontiers in aging neuroscience*, *15*, 1134775. https://doi.org/10.3389/fnagi.2023.1134775
2. Banerjee, R., Hazra, S., Ghosh, A. K., & Mondal, A. C. (2014). Chronic administration of bacopa monniera increases BDNF protein and mRNA expressions: a study in chronic unpredictable stress induced animal model of depression. Psychiatry investigation, 11(3), 297–306. https://doi.org/10.4306/pi.2014.11.3.297
3. Basheer, A., Agarwal, A., Mishra, B., Gupta, A., Padma Srivastava, M. V., Kirubakaran, R., & Vishnu, V. (2022). Use of Bacopa monnieri in the Treatment of Dementia Due to Alzheimer Disease: Systematic Review of Randomized Controlled Trials. *Interactive journal of medical research*, *11*(2), e38542. https://doi.org/10.2196/38542
4. Bonomi, C. G., Motta, C., Di Donna, M. G., Poli, M., Nuccetelli, M., Bernardini, S., Mercuri, N. B., Koch, G., & Martorana, A. (2024). Age of onset moderates the effects of Vascular Risk Factors on Neurodegeneration, Blood-Brain-Barrier permeability, and cognitive decline in Alzheimer's Disease. Alzheimer's research & therapy, 16(1), 248. https://doi.org/10.1186/s13195-024-01617-2
5. Can, B., & Sanlier, N. (2024). Alzheimer, Parkinson, dementia, and phytochemicals: insight review. Critical Reviews in Food Science and Nutrition, 1–23. https://doi.org/10.1080/10408398.2023.2299340
6. Dubey, T., Kushwaha, P., Thulasiram, H. V., Chandrashekar, M., & Chinnathambi, S. (2023). Bacopa monnieri reduces Tau aggregation and Tau-mediated toxicity in cells. *International journal of biological macromolecules*, *234*, 123171. https://doi.org/10.1016/j.ijbiomac.2023.123171
7. Fatima, U., Roy, S., Ahmad, S., Ali, S., Elkady, W. M., Khan, I., Alsaffar, R. M., Adnan, M., Islam, A., & Hassan, M. I. (2022). Pharmacological attributes of *Bacopa monnieri* extract: Current updates and clinical manifestation. *Frontiers in nutrition*, *9*, 972379. https://doi.org/10.3389/fnut.2022.972379
8. Ghosh, S., Kumar, V., Mukherjee, H., Saini, S., Gupta, S., Chauhan, S., Kushwaha, K., Lahiri, D., Sircar, D., & Roy, P. (2024). Assessment of the mechanistic role of an Indian traditionally used

ayurvedic herb Bacopa monnieri (L.)Wettst. for ameliorating oxidative stress in neuronal cells. *Journal of ethnopharmacology*, *328*, 117899. https://doi.org/10.1016/j.jep.2024.117899

9. Goyal, A., Gopika, S., Kumar, A., & Garabadu, D. (2022). A Comprehensive Review on Preclinical Evidence-based Neuroprotective Potential of *Bacopa monnieri* against Parkinson's Disease. *Current drug targets*, *23*(9), 889–901. https://doi.org/10.2174/1389450123666220316091734
10. Gregory, J., Vengalasetti, Y. V., Bredesen, D. E., & Rao, R. V. (2021). Neuroprotective Herbs for the Management of Alzheimer's Disease. Biomolecules, 11(4), 543. https://doi.org/10.3390/biom11040543
11. Gupta, V., & Prasad, S. (2024). Differential Alterations in the Expression of AMPA Receptor and Its Trafficking Proteins in the Hippocampus Are Associated with Recognition Memory Impairment in the Rotenone-Parkinson's Disease Mouse Model: Neuroprotective Role of Bacopa monnieri Extract CDRI 08. *Molecular neurobiology*, 10.1007/s12035-024-04392-1. Advance online publication. https://doi.org/10.1007/s12035-024-04392-1
12. Jerom, J. P., Madhukumar, S., Nair, R. H., & Narayanan, S. P. (2023). Anti-amyloid potential of some phytochemicals against Aβ-peptide and α-synuclein, tau, prion, and Huntingtin protein. Drug discovery today, 28(12), 103802. https://doi.org/10.1016/j.drudis.2023.103802
13. Mallick, D., Acharjee, A., Acharjee, P., & Trigun, S. K. (2024). Restoration of hippocampal adult neurogenesis by CDRI-08 (Bacopa monnieri extract) relates with the recovery of BDNF-TrkB levels in male rats with moderate grade hepatic encephalopathy. *International journal of developmental neuroscience : the official journal of the International Society for Developmental Neuroscience*, *84*(6), 510–519. https://doi.org/10.1002/jdn.10350
14. Marcos-Rabal, P., González-Fuentes, J., Castro-Vázquez, L., Lozano, M. V., Rodríguez-Robledo, V., Santander-Ortega, M. J., Selva-Clemente, J., Villaseca-González, N., & Del Mar Arroyo-Jiménez, M. (2021). Neurodegenerative Diseases: A Multidisciplinary Approach. Current pharmaceutical design, 27(30), 3305–3336. https://doi.org/10.2174/1381612827666210608152745
15. Nopparat, J., Sujipuli, K., Ratanasut, K., Weerawatanakorn, M., Prasarnpun, S., Thongbai, B., Laothaworn, W., & Inthima, P. (2024). Exploring the excellence of commercial Brahmi products from Thai online markets: Unraveling phytochemical contents, antioxidant properties and DNA damage protection. Heliyon, 10(2), e24509. https://doi.org/10.1016/j.heliyon.2024.e24509
16. Palollathil, A., Najar, M. A., Amrutha, S., Pervaje, R., Modi, P. K., & Prasad, T. S. K. (2024). Bacopa monnieri confers neuroprotection by influencing signaling pathways associated with interleukin 4, 13 and extracellular matrix organization in Alzheimer's disease: A proteomics-based perspective. *Neurochemistry international*, *180*, 105864. Advance online publication. https://doi.org/10.1016/j.neuint.2024.105864
17. Santos, A. F. D., Souza, M. M. Q., Amaral, E. C., Albuquerque, E. R., Bortoloti, D. S., Gasparotto Junior, A., Lourenço, E. L. B., Lovato, E. C. W., & Lívero, F. A. D. R. (2023). Bacopa monnieri in Patients with Parkinson's Disease: A Pilot Study. Journal of medicinal food, 26(2), 114–119. https://doi.org/10.1089/jmf.2022.0106
18. Shoukat, S., Zia, M. A., Uzair, M., Attia, K. A., Abushady, A. M., Fiaz, S., Ali, S., Yang, S. H., & Ali, G. M. (2023). Bacopa monnieri: A promising herbal approach for neurodegenerative disease treatment supported by in silico and in vitro research. Heliyon, 9(11), e21161. https://doi.org/10.1016/j.heliyon.2023.e21161
19. Singh, B., Pandey, S., Rumman, M., & Mahdi, A. A. (2020). Neuroprotective effects of Bacopa monnieri in Parkinson's disease model. *Metabolic brain disease*, *35*(3), 517–525. https://doi.org/10.1007/s11011-019-00526-w
20. Sushma, Sahu, M. R., Murugan, N. A., & Mondal, A. C. (2024). Amelioration of Amyloid-β Induced Alzheimer's Disease by Bacopa monnieri through Modulation of Mitochondrial Dysfunction and GSK-3β/Wnt/β-Catenin Signaling. Molecular nutrition & food research, 68(13), e2300245. https://doi.org/10.1002/mnfr.202300245
21. Valotto Neto, L. J., Reverete de Araujo, M., Moretti Junior, R. C., Mendes Machado, N., Joshi, R. K., Dos Santos Buglio, D., Barbalho Lamas, C., Direito, R., Fornari Laurindo, L., Tanaka, M., & Barbalho, S. M. (2024). Investigating the Neuroprotective and Cognitive-Enhancing Effects of *Bacopa monnieri*: A Systematic Review Focused on Inflammation, Oxidative Stress, Mitochondrial Dysfunction, and Apoptosis. *Antioxidants (Basel, Switzerland)*, *13*(4), 393. https://doi.org/10.3390/antiox13040393